)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Odinwell
Odinwell (ODIN) investor relations material
Odinwell Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary18 Aug, 2026
Executive summary
Achieved first commercial sales of novaQS systems to a leading Swedish veterinary institution, marking a key milestone toward commercialization and market readiness.
Focused on preparing for a broader product launch in veterinary medicine in Q4 2026, including scaling production and CE-marking activities.
Strengthened financial position through a directed share issue and a targeted Leo emission to board members and executives.
Intensified collaboration with major global wound care players, with active partnership discussions ongoing.
Financial highlights
Q2 2026 revenue was 706 KSEK, down from 976 KSEK in Q2 2025; H1 2026 revenue was 1,765 KSEK, down from 2,091 KSEK year-over-year.
Q2 2026 operating loss was -1,433 KSEK (improved from -1,704 KSEK in Q2 2025); H1 2026 operating loss was -2,610 KSEK (improved from -3,470 KSEK year-over-year).
Net loss for Q2 2026 was -1,434 KSEK (vs. -1,675 KSEK in Q2 2025); H1 2026 net loss was -2,585 KSEK (vs. -3,408 KSEK year-over-year).
Cash position at June 30, 2026 was 1,417 KSEK; proceeds from a 3.3 MSEK share issue to be recognized in Q3.
Outlook and guidance
Targeting launch of novaQS for veterinary medicine in Q4 2026, with ongoing preparations for production scale-up and regulatory approvals.
Continued focus on expanding partnerships in both veterinary and human wound care segments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Odinwell
- Veterinary focus accelerates commercialization, with improved results and strong equity position.ODIN
Q1 2026 - Revenue fell, losses narrowed, and commercialization in veterinary medicine is prioritized for 2026.ODINQ4 2025
- Stable revenue, continued losses, strong equity, and key R&D milestones achieved.ODINQ3 2025
- Revenue declined and losses continued, but clinical and technical milestones were achieved.ODINQ2 2025
- Q3 saw narrowed losses, strong cash position, and key product development milestones reached.ODINQ3 2024
- Stable losses and modest revenue growth as Odinwell advances wound care sensor development.ODINQ2 2024
- Q1 saw stable losses, new funding, and clinical progress as Odinwell targets growth.ODINQ1 2025
- Improved results and strategic progress in wound care tech mark Odinwell's 2024.ODINQ4 2024
Next Odinwell earnings date
Q3 202617 Nov, 2026
Odinwell
Next Odinwell earnings date
Q3 202617 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Odinwell is a Swedish medtech company focused on revolutionizing the field of wound care through its patented optical technology. This innovative approach allows for the assessment of covered wounds without the need to remove dressings, thus enabling more accurate and timely treatments. Odinwell's technology is particularly designed to enhance medical solution providers' offerings by incorporating optical sensors into dressings. These sensors can detect a range of biomarkers such as signs of infection, blood, fluids, and pressure, facilitating real-time, non-invasive wound assessment. The company is headquartered in Halmstad, Sweden, and its shares are listed on the Stockholm Stock Exchange.